Teriflunomide Accord is a medicine used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation attacks the protective covering (sheath) around nerves and damages the nerves themselves. Teriflunomide Accord is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Teriflunomide Accord is a ‘generic medicine’. This means that Teriflunomide Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Aubagio. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf). Teriflunomide Accord contains the active substance teriflunomide.
Therapeutic Indication
### Therapeutic indication Teriflunomide Accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).
Therapeutic Area (MeSH)
N/AATC Code
L04AA31
ATC Item
xl 04 aa 31
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/AEMA Name
Teriflunomide Accord
Medicine Name
Teriflunomide Accord
Aliases
N/ANo risk management plan link.